Core Viewpoint - Company announced a share buyback of 304,200 shares for a total cost of HKD 6.0713 million, indicating confidence in its financial position and future prospects [1] Group 1 - The buyback is scheduled for November 7, 2025, reflecting the company's strategic approach to enhance shareholder value [1] - The total number of shares repurchased is 304,200, which may positively impact the stock price by reducing the number of shares outstanding [1] - The total expenditure for the buyback amounts to HKD 6.0713 million, demonstrating the company's commitment to returning capital to shareholders [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

格隆汇11月6日丨荃信生物-B(02509.HK)公告，11月6日耗资200万港元回购8.9万股。 ...

Core Viewpoint - Company announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - Company will repurchase 89,200 shares at a total cost of HKD 1.9961 million [1] - The buyback is scheduled for November 6, 2025, suggesting a strategic timing for the repurchase [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月6日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月31日 | | 227,071,600 | | 0 | | 227,07 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇荃信生物醫藥股份有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02509 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 227,071,600 | RMB | | 1 RMB | | | 227,071,600 | | 增加 / 減少 (-) | | | | | | RMB | | | | | 本月底結存 | | | 227,071,600 | RMB | | 1 RMB | | | 227,071,600 | 本月底法定/註冊股本總額： ...

Core Viewpoint - 荃信生物-B (02509.HK) experienced a significant intraday increase of over 11%, with a current rise of 4.78%, trading at 22.82 HKD, and a transaction volume of 12.29 million HKD [1] Summary by Category - Stock Performance - The stock price of 荃信生物-B rose by over 11% during the trading session [1] - As of the latest update, the stock is up 4.78%, priced at 22.82 HKD [1] - The trading volume reached 12.29 million HKD [1]

Core Viewpoint - Zai Lab Limited (荃信生物-B) has entered into a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting dual antibody QX031N, which has led to a significant increase in its stock price [1] Group 1: Financial Aspects - Zai Lab will receive an upfront payment of $75 million and up to $995 million in milestone payments, along with potential tiered royalties from future product sales [1] - The stock price of Zai Lab increased by over 11% during trading, with a current price of HKD 22.82 and a trading volume of HKD 12.29 million [1] Group 2: Product and Market Potential - QX031N is a long-acting dual antibody targeting TSLP and IL-33, currently in the preclinical pipeline and has not yet entered clinical stages [1] - The agreement with Roche is seen as a validation of the company's innovative early research capabilities and recognition of the market potential in the autoimmune respiratory sector [1] - The transaction is considered rare due to the significant upfront payment and the clinical value of QX031N, which is comparable to TL1A dual antibodies in the IBD field, indicating a leading position and market potential globally for this target combination [1]

Core Viewpoint - The announcement of a global exclusive collaboration and licensing agreement between the company and Roche for the self-developed long-acting dual antibody QX031N has positively impacted the stock price, reflecting investor confidence in the company's innovation capabilities and market potential in the autoimmune sector [1][1]. Group 1: Collaboration Agreement - The company has entered into a global exclusive collaboration and licensing agreement with Roche for QX031N, granting Roche rights for research, development, registration, production, and commercialization [1][1]. - The agreement includes an upfront payment of $75 million and up to $995 million in milestone payments, along with potential future sales royalties [1][1]. Group 2: Product Details - QX031N is a long-acting dual antibody injection targeting TSLP and IL-33, currently in the preclinical pipeline and has not yet entered clinical stages [1][1]. - The collaboration is seen as a validation of the company's early-stage innovation capabilities and recognition of the market potential in the autoimmune respiratory sector [1][1]. Group 3: Market Implications - The transaction is considered rare due to the significant upfront payment and the collaboration with a major multinational corporation (MNC), indicating the clinical value of QX031N is comparable to TL1A dual antibodies in the inflammatory bowel disease (IBD) field [1][1]. - The combination of targets for QX031N is viewed as having a leading position and market potential globally [1][1].